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Accepted 25 June 2020The anti-PP1Pk is a rare antibody associated with recurrent miscarriages, mainly in the first half of pregnancy.
There seems to be a direct correlation between the antibody titer and risk of miscarriage. As this is a rare entity,
few case reports have been published. The most frequently proposed therapeutic approaches are double-
filtration plasmapheresis and plasma exchange therapy. The rationale behind them is to remove the cytotoxic
antibodies from maternal circulation. Here, we present the case of a 30-year-old woman with a history of two
spontaneous miscarriages and a pre-conception anti-PP1Pk antibody titer of 1:4. As soon as she became preg-
nant, she was placed on prednisolone and low-molecular-weight heparin (LMWH). Biweekly antibody titers
were performed throughout the entire gestation and remained below 1:16. As the titers were considered to be
low, plasmapheresis was not performed. The pregnancy was uneventful and she delivered a healthy newborn
child at 37 weeks of gestation, with no signs of anaemia.







The anti-PP1Pk, previously known as anti-Tja, is a natural occurring
antibody against P, P1 and Pk red cell antigens. Individuals in which
these antigens are absent are known as having a p phenotype [1]. This
phenotype is extremely rare, with an estimated worldwide prevalence
of 5.8:106 [2].
The anti-PP1Pk antibody has been associatedwith recurrentmiscar-
riages, mainly in the first half of pregnancy [3,4]. The risk seems to be
directly correlated with the anti-PP1Pk antibody titer and particularly
with IgG type antibodies that cross the placenta [5].
There is no specific treatment or primary prevention strategy as this
is a naturally occurring antibody [4].
After searching the MEDLINE (PubMed), Scopus, and Scielo data-
bases, the authors found that most published case reports of successful
pregnancies in p phenotype women describe the use of plasma ex-
change therapy or double-filtration plasmapheresis in their manage-
ment [3,4,6–10]. The main purpose of these therapeutic approaches is
to remove the cytotoxic antibodies from maternal circulation, as soon
as the pregnancy is confirmed, in order to maintain antibody titers be-
tween 1:16 and 1:32 [4]. There are few case reports that describe the
use of dydrogesterone or expectant management only [9,10].ando Fonseca, IC 19, 2760-276In the last 25 years, from 1994 to 2019, only nine cases of pregnan-
cies in women with anti-PP1Pk antibodies have been published in the
aforementioned databases [3,4,6,8–12].
Here, we present a case of a successful pregnancy in a p phenotype
woman, with a history of recurrent pregnancy loss, managed with
close surveillance, biweekly antibody titers, without the need for
plasma exchange therapy or double-filtration plasmapheresis.2. Case
A 30-year-old healthy Caucasian woman was referred for a pre-
conception appointment because she had previously had two spontane-
ous miscarriages. She had been evaluated at another institution during
the former gestations and after both miscarriages. During that evalua-
tion, chromosomic abnormalities, acquired thrombophilia, uterine
malformations and endocrine pathology were excluded.
After the first miscarriage, she had been diagnosed with an MTHFR
and PAI-1 heterozygosity. During the second pregnancy, she had been
placed on low-molecular-weight heparin (LMWH), yet miscarried
again. During the evaluation for recurrent pregnancy loss, three years
before thepresent assessment, shewas found to have antibodies against
PP1Pk, with a titer of 1:128.
Following the first pre-conception appointment and after exclusion
of other causes of recurrentmiscarriages, an anti-PP1Pk titer was deter-
mined. The patient serum was evaluated through indirect antiglobulin
test, against a panel of cells with a known phenotype, at 37 °C. The
2 S. Nascimento et al. / Case Reports in Women's Health 27 (2020) e00238existence of anti-PP1Pk antibody was confirmed, with a titer of 1:4. The
patient became pregnant one month after the test result.
As soon as the pregnancy was confirmed, at 5 weeks of gestation,
she was put on prednisolone 10 mg/day and prophylactic LMWH
40 mg/day. Anti-PP1Pk antibody titer was promptly measured and
repeated every two weeks throughout the entire pregnancy, with the
intention to perform plasmapheresis if the titers were to increase.
In the biweekly measurements, the anti-PP1Pk antibody titer
remained equal to or below 1:8. As the titers were so low, themultidis-
ciplinary team,which included obstetrics, internal medicine and immu-
nohematology specialists, decided not to perform plasmapheresis.
In the third trimester, shewas found to have iron deficiency (ferritin
5 μg/L and transferrin saturation 6%) without anaemia (haemoglobin
12.1 mg/dL) and was given 1 g of intravenous ferric carboxymaltose at
33 and 34 weeks. No other problems were observed.
At 36 weeks of gestation, autologous blood withdrawal was per-
formed and stored for potential future use.
The patient maintained the initial medication throughout the entire
pregnancy,whichwas uneventful. She had an elective caesarean section
at 37weeks of gestation and delivered a healthy girl, with a birthweight
of 2.445 g and an Apgar score 10–10 and no signs of anaemia.
3. Discussion
The P blood group was first described in 1927 and was believed to
comprise three antigens: P1, Pk, and P. In the current classification,
there are three different blood group systems, through which six anti-
gens are distributed, based on the glycosyltransferase necessary for
their synthesis. These blood group systems are: P1Pk, GLOB and FORS.
P1Pk includes the Pk, P1, andNOR antigens; theGLOB system comprises
the P and PX2 antigens; and the FORS system, the Forssman antigen. The
P and Pk are high-frequency antigens and are present in more than
99.9% of people [1].
The different phenotypes are dependent on the type of glycosyl-
transferase that is mutated. The p phenotype, which is the null of this
blood group system, is a recessive trait and results from inactivating
mutations in the A4GALT1 gene in chromosome 22q13.2, which is re-
sponsible for 4-α-galactosyltransferase synthesis. In the absence of
this enzyme, Pk, P, and P1 antigens are not synthesized [1].
When the P, P1 and Pk antigens are absent, the anti-PP1Pk antibod-
ies, which are composed of regular IgM type, regular or irregular IgG
type antibodies, or a combination of both, naturally arise. The cytotoxic
components seem primarily to belong to the IgG3 subclass. These anti-
bodies cross the placental barrier, are efficient complement activators,
and are responsible for antibody-mediated cytotoxicity, although not
exclusively [13].
The presence of anti-PP1Pk antibody in women of reproductive age
is associated with early recurrent miscarriage and, only to a minor de-
gree, haemolytic disease in the newborn [3]. It is reported that 50–72%
of miscarriages occur in the first 20 weeks of gestation [4]. It has been
shown that the placenta contains a high density of Pk and P antigens,
which appear on the trophoblast as early as the 3rd week of gestation.
Antibodies against these antigens have been implicated in recurrent
pregnancy loss [4]. The P1 antigen arises only in the 19thweek of gesta-
tion and it has been proposed that it blocks the expression of other an-
tigens, lowering the cytotoxic effect of anti-P and anti-Pk antibodies [4].
Even though the placenta seems to be the most important target of the
anti-PP1Pk antibody complex, the precise mechanism of recurrent mis-
carriages is not completely understood [3,10].
Regarding management, there is no specific treatment for PP1Pk
alloimmunization. Contrary to Rh and Kell alloimmunization, in which
plasmapheresis is especially important in the last trimester, in anti-
PP1Pk pregnancies, pre-conception surveillance and early treatmentif
necessary) are essential [6].
Plasma exchange therapy and double-filtration plasmapheresis have
been used as therapeutic approaches [3,4,6,8,11,12]. The main purposeis to reduce antibody titers to 1:16 to 1:32, thereby preventing cytotox-
icity and miscarriage. Treatment should begin as soon as the pregnancy
is confirmed and should bemaintained until at least the 18th week ges-
tation. Its duration is controversial, however, especially beyond the 20th
week of gestation [4,8].
In the present case, the patient had a high titer – 1:128 – after the
second miscarriage, but the titer was spontaneously low – 1:4 – just
before her first successful pregnancy, probably because anti-PP1Pk anti-
body occurs naturally. During the reported gestation, as the titer
remained below 1:16, the multidisciplinary team decided not to
perform plasmapheresis.
The patient was put on prednisolone and LMWH as soon as she
became pregnant. Even though their use is currently controversial, cor-
ticosteroids were used for their known anti-inflammatory and immu-
nosuppressive effects on T and NK cells, which seem to be altered in
cases of recurrent miscarriages [14]. Although there is no consensus re-
garding the dosing and length of treatment, low-dose corticosteroids
seem to increase pregnancy success without significantly increasing
the risks [14,15]. The use of LMWH might also be arguable, on the one
hand because MTHFR and PAI-1 mutations are presently of unknown
clinical significance and on the other hand because there are studies in
which prophylactic enoxaparin did not improve the chance of a live
birth in women with a history of recurrent pregnancy loss [16]. Never-
theless, in other studies LMWH has shown to significantly lower the
rate of miscarriage in womenwith a history of unexplainedmiscarriage
negatively tested for antiphospholipid antibodies [17]. Besides inhib-
iting coagulation, heparin has anti-inflammatory effects, by blocking
the activation of complement and preventing leukocyte adhesion to
vascular endothelial cells and subsequent transmigration, withminimal
adverse effects at prophylactic doses [18,19].
As described, in the third trimester the patient was found to have
iron deficiency and was treated with ferric carboxymaltose at 33 and
34 weeks. Intravenous iron was chosen, as it increases haemoglobin
and ferritin levels faster and more efficaciously, with fewer side-
effects than oral iron, which was particularly important in this situation
as there was a need to lessen the need for blood transfusion, since it
would be very difficult to find compatible units for a patient with such
a rare phenotype [20].
For the same reason, blood should be drawn before delivery, for pos-
sible future autologous transfusions [4]. These patients should be en-
couraged to become blood donors, for potential use by themselves or
others with the same phenotype [10].
In conclusion, as the p phenotype is extremely rare, with few pub-
lished case reports, little is known about the pregnancy management
of women with this condition. In the presented case, antibody titers
were assessed biweekly throughout the entire pregnancy and sponta-
neously remained below 1:16. We hypothesize that prednisolone
might have had an effect on the persistently low antibody titers. For
that reason, the multidisciplinary team decided not to perform plasma-
pheresis. Even though we do not know the extent of the impact that
prednisolone and LMWH therapy had on the final result, we propose
that p phenotype pregnancies can be safely managed without plasma-
pheresis or plasma exchange therapy, if the titers remain below 1:16,
emphasizing the importance of repeat antibody titers, at least biweekly.Contributors
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